Summary of the interim report
The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480.

Fourth quarter 2023 for the group
Income amounted to TSEK 78 (0).
Loss before tax totalled TSEK 12,175 (loss: 23,384).
Loss per share was SEK 0.03 (loss: 0.09).

The year 2023 for the group
Income amounted to TSEK 78 (0).
Loss before and tax totalled TSEK 58,367 (loss: 73,165).
Loss per share was SEK 0,13 (loss: 0,37).

Fourth quarter 2023 for the parent company
Income amounted to TSEK 78 (6,288).
Loss before tax totalled TSEK 9,467 (loss: 7,323).
Loss per share was SEK 0.03 (loss: 0.07).

The year 2023 for the parent company
Income amounted to TSEK 78 (6,288).
Loss before tax totalled TSEK 39,935 (loss: 39,109).
Loss per share was SEK 0,10 (loss: 0,25).
At December 31, 2023, the equity/assets ratio was 78% (66).

 
Significant events in the fourth quarter of 2023
Xintela’s stem cell product, XSTEM, has been assessed as safe at all dose levels in knee osteoarthritis clinical study. (October 10, 2023)
Xintela publishes results for the exercise of warrants of series TO3, whereby Xintela receives around SEK 6.3 million. (December 7, 2023)
Xintela publishes efficacy results with EQSTEM from preclinical equine OA study. (December 20, 2023)
First patient dosed in Xintela's clinical study on difficult-to-heal leg ulcers. (December 21, 2023)

Significant events after the end of the period
Xintela appoints Lucienne Vonk as Chief Scientific Officer. (February 19, 2024)

The complete report is available for download below and on the company’s website www.xintela.se/en/investors#reports.